CHAPTER 2.1 36 Supplementary table 1 (continued). Characteristics, inclusion and exclusion criteria of trials Study name BEAUTIFUL CONFIRM-HF FAIR-HF PANTHEON SHIFT Background cardiovascular treatment had to be considered optimal by the investigator, and should, in principle, include betablockers, statins, ACEI or ARB, and antiplatelet drugs On optimal background therapy for at least 4 weeks with no dose changes of HF drugs during the last 2 weeks (with the exception of diuretics). In general, optimal pharmacological treatment should include an ACEI or ARB and a betablocker unless contraindicated or not tolerated and diuretic if indicated. On optimal conventional therapy (optimal pharmacological treatment which includes a diuretic, a beta-blocker, and/or an ACEI or ARB as determined by the investigator, unless contraindicated or not tolerated). No dose changes of heart failure drugs during the last 2 weeks (with the exception of diuretics). No introduction of a new heart failure drug class during the last 4 weeks. Optimized and unchanged CHF medications or dosages, for at least 4 weeks prior to selection. Haemoglobin≥ 110 g/L (in males) or ≥100 g/L (in females) a Screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations as measured locally by HemoCue® analyzer Haemoglobin ≥ 10 g/dL within 3 months prior to randomization. If several values are available, the latest result should be used. a Serum haemoglobin ≥ 110 g/L (≥11 g/dL) a
RkJQdWJsaXNoZXIy MjY0ODMw